[
  {
    "ts": "2025-07-14T11:38:50+00:00",
    "headline": "India's Sun Pharma launches hair loss drug Leqselvi in US after patent settlement",
    "summary": "(Reuters) -India's top drugmaker by revenue Sun Pharma on Monday launched its anti-baldness drug Leqselvi in the U.S., following the settlement of a patent dispute with Incyte Corp.  The company said 8 mg Leqselvi tablets for severe alopecia areata will be available in the U.S., after a launch delay caused by a patent infringement case in a U.S. court.  Shrikant Akolkar, analyst at Nuvama Institutional Equities, said the drug could generate up to $400 million in sales by FY30, with peak sales potential of $900 million, and boost growth in Sun's key U.S. market.",
    "url": "https://sg.finance.yahoo.com/news/indias-sun-pharma-launches-anti-113850909.html",
    "source": "Reuters",
    "provider": "yfinance",
    "raw": {
      "id": "ee6924f7-7db1-3bb8-b9fe-71c1be04d19a",
      "content": {
        "id": "ee6924f7-7db1-3bb8-b9fe-71c1be04d19a",
        "contentType": "STORY",
        "title": "India's Sun Pharma launches hair loss drug Leqselvi in US after patent settlement",
        "description": "",
        "summary": "(Reuters) -India's top drugmaker by revenue Sun Pharma on Monday launched its anti-baldness drug Leqselvi in the U.S., following the settlement of a patent dispute with Incyte Corp.  The company said 8 mg Leqselvi tablets for severe alopecia areata will be available in the U.S., after a launch delay caused by a patent infringement case in a U.S. court.  Shrikant Akolkar, analyst at Nuvama Institutional Equities, said the drug could generate up to $400 million in sales by FY30, with peak sales potential of $900 million, and boost growth in Sun's key U.S. market.",
        "pubDate": "2025-07-14T11:38:50Z",
        "displayTime": "2025-07-14T11:38:50Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/reuters.com/79b132635fa59c34ac2f07777ef24828",
          "originalWidth": 800,
          "originalHeight": 504,
          "caption": "A bird flies past the logo of Sun Pharmaceutical Industries Ltd. installed on the facade of its corporate office in Mumbai",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/YJm2_1CmJIU9OTdDDle3hQ--~B/aD01MDQ7dz04MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/reuters.com/79b132635fa59c34ac2f07777ef24828.cf.webp",
              "width": 800,
              "height": 504,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/SGrfH86XfaU28EeHNOBhPg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/reuters.com/79b132635fa59c34ac2f07777ef24828.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Reuters",
          "url": "https://www.reuters.com/"
        },
        "canonicalUrl": {
          "url": "https://sg.finance.yahoo.com/news/indias-sun-pharma-launches-anti-113850909.html",
          "site": "finance",
          "region": "SG",
          "lang": "en-SG"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/indias-sun-pharma-launches-anti-113850909.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "SUNPHARMA.NS"
            },
            {
              "symbol": "INCY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]